This is a major step in our progression; helping to fulfill our vision of becoming an international Bio Pharmaceutical Company Headquartered in Texas.
HOUSTON (PRWEB)
June 08, 2020
Greffex, a leading genetic engineering company, with the world’s first universal vaccine platform delivered through the use of proprietary clean viral vectors, recently announced a key manufacturing agreement with FUJIFILM Diosynth Biotechnologies to produce its vaccine in the United States. Greffex’s platform is the world’s most successful gene therapy delivery vehicle (vector) with broad applications for delivering treatments including vaccines, immune suppression and gene therapy.
“We are delighted to be selected by Greffex as their CDMO (Contract Development & Manufacturing Organization) partner,” said Gerry Farrell, chief operating officer, FDB Texas site. “FDB looks forward to our work together to bring these ground-breaking therapies to market to meet the critical need for global vaccines. ”
John R. Price, Greffex Co-Chairman of the Board, President and CEO said “Greffex is excited to be working with FUJI Diosynth. This is a major step in our progression; helping to fulfill our vision of becoming an international Bio Pharmaceutical Company Headquartered in Texas creating innovative therapies to protect and heal mankind.”
In 2019, Greffex was awarded an $18.9 million contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. This award will enable Greffex to develop and exploit its GreVac(TM) Plug-And-Play Technology to expedite the production of vaccine candidates for biodefense and emerging infectious diseases to target infectious threats, whether natural or man-made.
Greffex, a leading genetic engineering company founded in 2005, has developed the world’s first universal vaccine platform that delivers unprecedented time-to-market, cost efficiency, efficacy and safety through the use of proprietary clean viral vectors. The company has 14 vaccines in its development portfolio, numerous gene therapies in development including Hemophilia A and Usher Syndrome, and immune tissue engineering aimed at overcoming transplant rejection.
Greffex is headquartered in Houston, Texas with laboratories in Aurora, Colorado.
Share article on social media or email: